Zacks Research Has Negative Estimate for Amgen Q1 Earnings

Amgen Inc. (NASDAQ:AMGN) – Equities research analysts at Zacks Research lowered their Q1 2025 EPS estimates for Amgen in a report issued on Tuesday, February 25th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $4.17 per share for the quarter, down from their previous forecast of $4.56. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share. Zacks Research also issued estimates for Amgen’s Q1 2026 earnings at $4.49 EPS, Q2 2026 earnings at $5.08 EPS, Q3 2026 earnings at $5.17 EPS, Q4 2026 earnings at $5.33 EPS, FY2026 earnings at $20.07 EPS and FY2027 earnings at $21.18 EPS.

Other analysts have also issued reports about the stock. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Bank of America raised their price objective on shares of Amgen from $256.00 to $275.00 and gave the stock an “underperform” rating in a report on Thursday, February 6th. William Blair restated an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Piper Sandler raised their price objective on shares of Amgen from $310.00 to $329.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Finally, Wolfe Research started coverage on shares of Amgen in a report on Friday, November 15th. They issued a “peer perform” rating for the company. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $314.09.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $305.82 on Thursday. The company has a market cap of $164.29 billion, a price-to-earnings ratio of 40.51, a price-to-earnings-growth ratio of 2.63 and a beta of 0.56. The company has a 50-day moving average price of $279.97 and a 200-day moving average price of $300.24. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. Amgen has a 12 month low of $253.30 and a 12 month high of $346.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%.

Institutional Investors Weigh In On Amgen

A number of large investors have recently added to or reduced their stakes in AMGN. Capital World Investors boosted its stake in shares of Amgen by 1,292.0% during the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company’s stock worth $1,693,042,000 after acquiring an additional 6,029,058 shares during the last quarter. Norges Bank purchased a new position in shares of Amgen during the 4th quarter worth $1,541,991,000. Capital International Investors boosted its stake in shares of Amgen by 40.1% during the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company’s stock worth $3,182,843,000 after acquiring an additional 3,495,503 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Amgen by 25.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company’s stock worth $3,441,909,000 after acquiring an additional 2,672,975 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Amgen during the 4th quarter worth $401,913,000. Institutional investors own 76.50% of the company’s stock.

Insiders Place Their Bets

In other Amgen news, EVP David M. Reese sold 25,225 shares of Amgen stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the sale, the executive vice president now owns 36,922 shares of the company’s stock, valued at approximately $11,240,533.68. The trade was a 40.59 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 69,341 shares of company stock valued at $20,644,335. Company insiders own 0.69% of the company’s stock.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.11%. The ex-dividend date is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s payout ratio is 126.09%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.